Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17658848 | 0.93 | DPP7 (0.31) | L3MBTL1 | |
| SCHEMBL2603332 | 0.93 | SLC18A3 (0.32) | L3MBTL1 | |
| SCHEMBL2603338 | 0.93 | SLC18A3 (0.32) | L3MBTL1 | |
| SCHEMBL2603339 | 0.93 | SLC18A3 (0.32) | L3MBTL1 | |
| SCHEMBL13910189 | 0.93 | SLC18A3 (0.32) | L3MBTL1 | |
| SCHEMBL25124990 | 0.93 | — | — | |
| SCHEMBL11947594 | 0.91 | SLC18A3 (0.35) | — | |
| SCHEMBL11947597 | 0.91 | SLC18A3 (0.35) | — | |
| SCHEMBL13910193 | 0.91 | SLC18A3 (0.35) | — | |
| SCHEMBL20319179 | 0.87 | SLC18A3 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023168298-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11339184-B2 | Antibacterial compounds, compositions thereof, and methods using same | THE ROCKEFELLER UNIVERSITY (US) | 2022-05-24 | — | — | US | disclosed |
| WO-2021242849-A1 | ANTIBACTERIAL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS USING SAME | THE ROCKEFELLER UNIVERSITY (US) | 2021-12-02 | — | — | WO | disclosed |
| US-20210238164-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20210024562-A1 | ANTIBACTERIAL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS USING SAME | THE ROCKEFELLER UNIVERSITY | 2021-01-28 | — | — | US | disclosed |
| US-20210002254-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-01-07 | — | — | US | disclosed |
| US-10766877-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10604507-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-31 | — | — | US | disclosed |
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | L3MBTL1 4237/4885L3MBTL3 4357/4885 |
| US-11339184-B2 | Antibacterial compounds, compositions thereof, and methods using same | CLPP, MPO, SPOUT1 | L3MBTL1 2640/4885L3MBTL3 2172/4885 |
| US-20210238164-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | L3MBTL1 4237/4885L3MBTL3 4357/4885 |
| US-10604507-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | L3MBTL1 4237/4885L3MBTL3 4357/4885 |
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | L3MBTL1 4237/4885L3MBTL3 4357/4885 |
| US-20210002254-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | L3MBTL1 4237/4885L3MBTL3 4357/4885 |
| US-10766877-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | L3MBTL1 4237/4885L3MBTL3 4357/4885 |
| US-20210024562-A1 | ANTIBACTERIAL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS USING SAME | CLPP, MPO, SPOUT1 | L3MBTL1 2640/4885L3MBTL3 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.